Hemo Organic Advances Capital Raise

2.76 crore rupees received as second tranche payment.
34 lakh warrants set for potential conversion into equity shares.

Reader Takeaway: The receipt of funds initiates warrant conversion, which will result in equity dilution for existing shareholders.

What just happened

Hemo Organic Ltd announced that its Board of Directors acknowledged the receipt of the second tranche of consideration for convertible warrants during their meeting on September 17, 2026. The company successfully collected Rs 2,76,25,000 from two non-promoter entities, Vacro Enterprises Pvt Ltd and Qmin Realities Pvt Ltd. Each entity holds 17,00,000 warrants, totaling 34,00,000 warrants currently awaiting conversion.

Why this matters

This payment marks a key milestone in the company's capital-raising process. Once the remaining formalities are concluded, the 34 lakh warrants will be converted into equity shares with a face value of Rs 10 each. This transaction serves as a significant liquidity event for the company, though it is a precursor to a substantial change in the shareholding structure.

Projected Share Capital Change

The conversion will lead to a notable increase in the company's equity base. The current paid-up share capital of Rs 3,46,59,000, represented by 34,65,900 shares, is expected to expand to Rs 6,86,59,000, comprising 68,65,900 shares following the full conversion of the warrants.

Risks to watch

Investors should note the dilutive impact of this conversion. As the number of outstanding shares increases significantly, the earnings per share (EPS) for current shareholders will be diluted. Future filings should be monitored for the final allotment of these shares and any potential regulatory updates required to finalize the process.

What to track next

Shareholders should look for official announcements regarding the formal allotment of equity shares and any subsequent filings that confirm the completion of the conversion process.